संचार मंत्रालय के राज्य मंत्री (श्री राम नियाल भिर्धाः (क) 31-10-85 को इलाहाबाद में, 8,513 टेलोफल कनैक्शन कार्य कर रहे थे।

(ख) 31-10-85 को इलाह वाद में नए टेलोंफोन कनेक्शनों के लिए 1621 नाम प्रतीक्षा-सूची में थे।

(ग) सातवीं योजना के दौरान वर्त-मान प्रतीक्षा-सूत्री को उत्तरोत्तर निपटाए जाने की संभावना है।

## Curtailment of production of essential drags by M/s Glaxo Laboratories

2209. SHRI PRAVIN KUMAR PRAJA. PATI; Will the Minister of INDUSTRY be pleased to state:

(a) Whether it  $i_s$  a fact that according to the balance sheets of M|s. Glaxo Laboratories for period ending 30th June, 1984 and 1985 they indicated a continuous process <sup>of</sup> curtailment of production of essential medicine^ such as Vaccines and Antibiotics and excess production of ointments, tablets, liquid, and capsules,

(b) whether that the production of tablets, capsules, ointments and liquids in eight to ten times more than permitted capacity of each whereas production of vaccines and antibiotics indicates srortfall in the same ratio;

(c) if so, what are the reasons therefor;

(d) whether there is any provision under I (D&R) Act or Drug Policy to check unauthorised production and insist obligation of production of essential drugs; and

(e) if so, what 'are the details thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) to (c) The company tailors its production to the market demand; however, the company conforms to the ratio parameters eligible under the 1978 Drug Policy.

(d) and (e) Under the KD&R) Act. manufacture without a valid industrial approval  $i_s$  'an offence. A Company cannot be compelled to produce a particular product, whether essential or not.

## **Anti-TB Drug**

2210. SHRI PRAVIN KUMAR PRAIA PATI; Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 965 given in the Rajya Sabha on the 25th November, 1985 and state:

(a) whether Ethambutol and Rifampicin are Anti-TB and Anti-Leprosy drugs;

(b) what is the mark up allowed on formulations based on these drugs and what is the mark up allowed on other anti-TB and Leprosy drugs alongwith name of each drug and mark up allowed in each case;

(c) whether it is a fact that since 1980 formulator<sub>s</sub> have been making unintended benefits on these medicines if so what is the total amount worked out on these two drug<sub>s</sub> upto 30th November 1985;

(d) when did it come to the notice of Government;

(e) what are the names of companies to whom notices were issued along with date;

(f) what are the details of amount so far recovered on these medicines;

(g) whether it is also a fact that Ethambutol is available in open market at Rs. 550|per Kg; and

(h) if so., what steps were taken to reduce the prices of Ethambutol formulations?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R- K. JAICHANDRA SINGH): (a) Rifampin  $i_{\rm s}$  an Anti-T.B. and Anti-Lenrosv drue whereas Ethambutol  $i_{\rm s}$  an Anti-T.B. drug only.

(b) Mark-up is allowed in accordance with the provisions of Drues (Prices Control) Order, 1979 on Anti-T.B. and Anti-Leprosy drug.

(c) On account of the difference between the price of Rifamycin allowed in the formulations and the actual landed cost of imnort in snite of six redn<sup>o</sup>n in r.n~s between Aueust 1981 and September 19\*4 certain excess amount had accrued to the